Danaher/Beckman Coulter
On February 7, 2011, Danaher (NYSE: DHR) and Beckman Coulter, Inc. (NYSE: BEC) announced that they have entered into an agreement whereby Danaher will acquire Beckman for $83.50 per share in cash, or a total consideration of $6.8 billion.
Closing is expected in H111.
The transaction is structured as a tender offer for all outstanding shares of Beckman Coulter followed by a merger.
Goldman, Sachs & Co. is acting as financial advisor to Beckman Coulter in connection with the transaction.
Latham & Watkins, LLP is serving as legal counsel to Beckman Coulter in connection with the transaction.
Closing is expected in H111.
The transaction is structured as a tender offer for all outstanding shares of Beckman Coulter followed by a merger.
Goldman, Sachs & Co. is acting as financial advisor to Beckman Coulter in connection with the transaction.
Latham & Watkins, LLP is serving as legal counsel to Beckman Coulter in connection with the transaction.
View Older Stories
-
Armonica Announces Appointment of Emily Milsovic as CEO
-
Liquid Handling System Market to Reach USD 6.7 Billion by 2031 Driven by Rising Investments in Drug Discovery and Automation
-
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
-
Beckman Coulter and MeMed Extend Partnership Advancing Host Immune Response Diagnostics
-
Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry
-
AdaptHealth Corp. (AHCO) Appoints Suzanne Foster as Chief Executive Officer
-
AdaptHealth Appoints Suzanne Foster as Chief Executive Officer
-
Flow Cytometry Market to Surge to USD 8.96 billion in 2031: Analysis of the Industry, Technologies, Pricing, and Competitors
-
Beckman Coulter's DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global
-
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics
-
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics
-
Armonica Technologies announces Emily Milsovic joins Board of Directors
-
Beckman Coulter Diagnostics Appoints Kevin O'Reilly as New President
-
Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance
-
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
-
Composite Alliance Group Announces Appointment of Chief Executive Officer of Techni Modul Engineering S.A.
-
KKR Completes Acquisition of Industrial Physics, Welcomes Barry Lyon as Chief Executive Officer and Lance Reisman as Chairman
-
Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
-
Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance
-
Beckman Coulter Connects Scopio Labs Digital Cell Morphology with Hematology Workcell Extending Automated Workflow
-
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
-
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics
-
Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance
-
Sonendo Announces New Leadership in Operations and R&D
-
Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Bacterial and Viral Infections
-
Beckman Coulter Acquires Artificial Intelligence Company Providing Evidence-Based Clinical Decision Support for Emergency Departments
-
Beckman Coulter Partners with Mass General and BARDA to Identify Severe Pediatric Infections in Emergency Departments
-
Beckman Coulter and Scopio Labs Partner to Accelerate Adoption of Hematology Digital Cell Morphology Platform
-
Cue Health Appoints Allison Blackwell Chief Human Resources Officer
-
Covalon Announces New Senior Vice President of Marketing
-
Saladax Biomedical, Inc. Announces Global Distribution Agreement With Beckman Coulter, Inc. for Antipsychotic Drug Tests
-
Beckman Coulter Introduces Antipsychotic Drug Testing to Address Unmet Clinical Need for More Than 69 Million People Living with Serious Mental Conditions
-
BioTech Company PathogenDx Strengthens Executive Team; Announces Several New Key Leadership Appointments
-
Gold Sponsor Molecular Devices at Society for Laboratory Automation and Screening 2022 International Conference and Exhibition
-
Beckman Coulter Life Sciences selects Vodori's Pepper Flow to improve compliance and optimize their promotional review process
-
Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4%(1) and cutting sample processing time by up to 78%(2)
-
Mike Musgnug Joins Discovery Life Sciences Global Executive Leadership Team As Chief Revenue Officer
-
Demaris Mills Appointed President of IDT
-
Global Cell Therapy Technologies Market Report 2021: Consumables; Equipment; Systems; Software - Long-term Forecast to 2025 & 2030
-
Beckman Coulter to Distribute BNP Cardiac Assay to Customers
-
Hochuen Medical Raises Tens of Millions RMB in Series A Financing
-
/C O R R E C T I O N -- Beckman Coulter Diagnostics/
-
Beckman Coulter Launches First Fully Quantitative and Automated COVID-19 IgG Test to Assess Antibody Immune Response Levels
-
Beckman Coulter is First Diagnostics Company to Offer Workflow Automation Specifically for Mid-volume Laboratories
-
Waters Corp. (WAT) Announces Amol Chaubal named Waters Chief Financial Officer
-
Waters Corporation Continues Transformation with Planned Leadership Transitions
-
/C O R R E C T I O N -- Beckman Coulter Diagnostics/
-
Danaher (DHR) Announces Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA
-
Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA
-
Beckman Coulter Offers $4/High-throughput Antigen Test to Support U.S. Government Initiative to Expand COVID-19 Testing

